COVINGTON & BURLING LLP for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Biopharmaceutical innovation and intellectual property policy issues; Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KRISTA CARVER | — |
| NATALIE DERZKO | — |
Health Issues HCR
Maintaining Investments in New Innovation Act (S. 476); Interagency Patent Coordination and Improvement Act of 2023 (S. 79/H.R. 1717); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338); Ensuring Timely Access to Generics Act of 2021 (S. 562); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KRISTA CARVER | — |
| NATALIE DERZKO | — |
| ANDREW DAVID LAZEROW | — |
| ROBERT ALLEN LONG New | — |
| JENNIFER L PLITSCH | — |
| MICHAEL STERN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.